Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 701–800 of 1,018
A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure
Miner, E. C., & Miller, W. L. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.1.71 · Cited by 86
Approach and Management of Hypertension After Kidney Transplantation
Tantisattamo, E., Molnar, M. Z., Ho, B., Reddy, U. G., Dafoe, D. C., Ichii, H., Ferrey, A., Hanna, R. M., Kalantar‐Zadeh, K., & Amin, A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00229 · Cited by 96
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension
Chiang, C., Wang, T., Li, Y.-H., Lin, T., Chien, K., Yeh, H., Shyu, K., Tsai, W.-C., Chao, T.-H., Hwang, J., et al. (2010) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(10)60120-9 · Cited by 90
Plasma Apelin Concentration is Depressed Following Acute Myocardial Infarction in Man
Weir, R. A. P., Chong, K. S., Dalzell, J. R., Petrie, C. J., Murphy, C. A., Steedman, T., Mark, P. B., McDonagh, T. A., Dargie, H. J., & McMurray, J. J. V. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp043 · Cited by 86
Rigsby, C. S., Pollock, D. M., & Dorrance, A. M. (2007) · Microvascular Research · doi:10.1016/j.mvr.2006.12.001 · Cited by 86
Cost-effectiveness of heart failure therapies
Rohde, L. E. P., Bertoldi, E. G., Goldraich, L. A., & Polanczyk, C. A. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.60 · Cited by 97
Clinical and Genetic Correlates of Serum Aldosterone in the Community: The Framingham Heart Study
KATHIRESAN, S., LARSON, M., BENJAMIN, E., COREY, D., MURABITO, J., FOX, C., WILSON, P., RIFAI, N., MEIGS, J., & RICKEN, G. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.12.005 · Cited by 86
Arai, K., Tsuruoka, H., & Homma, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.028 · Cited by 87
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
Rico-Mesa, J. S., White, A., Ahmadian-Tehrani, A., & Anderson, A. S. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01399-7 · Cited by 94
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Pandey, A. K., Bhatt, D. L., Cosentino, F., Marx, N., Rotstein, O. D., Pitt, B., Pandey, A., Butler, J., & Verma, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac299 · Cited by 96
Self-citationBauersachs, J. K., Solomon, S. D., Anker, S. D., Antorrena, I., Bátkai, S., Viereck, J., Rump, S., Filippatos, G. S., Granzer, U., Ponikowski, P. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3139 · Cited by 91
Liu, L. C. Y., Schutte, E., Gansevoort, R. T., van der Meer, P., & Voors, A. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1059819 · Cited by 91
Early Aldosterone-Regulated Genes in Cardiomyocytes: Clues to Cardiac Remodeling?
Fejes‐Tóth, G., & Náray‐Fejes‐Tóth, A. (2007) · Endocrinology · doi:10.1210/en.2006-1438 · Cited by 91
RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials
von Lueder, T. G., & Krum, H. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6424-y · Cited by 87
Heart Failure in Children: Etiology and Treatment
Rossano, J. W., & Shaddy, R. E. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.04.055 · Cited by 92
Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., Mega, J. L., Menon, V., Page, R. L., II, & Newby, L. K. (2015) · Circulation · doi:10.1161/cir.0000000000000183 · Cited by 96
Liu, S., Xie, Z., Daugherty, A., Cassis, L. A., Pearson, K. J., Gong, M. C., & Guo, Z. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300820 · Cited by 87
Seeger, F. H., Rasper, T., Koyanagi, M., Fox, H., Zeiher, A. M., & Dimmeler, S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.194688 · Cited by 92
Fenske, W. K., Wanner, C., Allolio, B., Drechsler, C., Blouin, K., Lilienthal, J., & Krane, V. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070691 · Cited by 89
Kjeldsen, S. E. (2004) · Heart Drug · doi:10.1159/000076263 · Cited by 84
Glucocorticoid treatment and cardiovascular disease
Ng, M. K. C., & Celermajer, D. S. (2004) · Heart · doi:10.1136/hrt.2003.031492 · Cited by 95
Sürder, D., Schwitter, J., Moccetti, T., Astori, G., Rufibach, K., Plein, S., Cicero, V. L., Soncin, S., Windecker, S., Moschovitis, A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.03.039 · Cited by 84
Karram, T., Abbasi, A. H., Keidar, S., Golomb, E., Hochberg, I., Winaver, J. M., Hoffman, A., & Abassi, Z. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01186.2004 · Cited by 84
Weber, T., Lang, I. M., Zweiker, R., Horn, S., Wenzel, R. R., Watschinger, B., Slany, J., Eber, B., Roithinger, F. X., & Metzler, B. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0998-5 · Cited by 101
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
Georgianos, P. I., & Agarwal, R. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.027 · Cited by 87
Judge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 91
Placental growth factor mediates aldosterone-dependent vascular injury in mice
Jaffe, I. Z., Newfell, B. G., Aronovitz, M. A., Mohammad, N. N., McGraw, A. P., Perreault, R. E., Carmeliet, P., Ehsan, A., & Mendelsohn, M. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40205 · Cited by 87
Lund, L. H., & MANCINI, D. M. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.03.003 · Cited by 96
Interactions between the sympathetic nervous system and the RAAS in heart failure
Goldsmith, S. R. (2004) · Current Heart Failure Reports · doi:10.1007/s11897-004-0024-5 · Cited by 92
Weiner, R. B., Baggish, A. L., Chen-Tournoux, A., Marshall, J. E., Gaggin, H. K., Bhardwaj, A., Mohammed, A. A., Rehman, S. U., Barajas, L., Barajas, J., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs180 · Cited by 84
2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.023 · Cited by 86
Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., & Koch, W. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.08.635 · Cited by 83
Nuclear Shuttling Precedes Dimerization in Mineralocorticoid Receptor Signaling
Großmann, C., Ruhs, S., Langenbruch, L. M., Mildenberger, S., Strätz, N., Schumann, K., & Gekle, M. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.04.014 · Cited by 83
Nediani, C., Raimondi, L., Borchi, E., & Cerbai, E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3198 · Cited by 88
Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling
Zhang, A. D., Cat, A. N. D., Soukaseum, C., Escoubet, B., Cherfa, A., Messaoudi, S., Delcayre, C., Samuel, J., & Jaisser, F. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.117531 · Cited by 83
Clinical Management and Prevention of Sudden Cardiac Death
Yousuf, O. K., Chrispin, J., Tomaselli, G. F., & Berger, R. D. (2015) · Circulation Research · doi:10.1161/circresaha.116.304555 · Cited by 92
Management of Adult Patients with Ascites Due to Cirrhosis: An Update†
Runyon, B. A. (2009) · Hepatology · doi:10.1002/hep.23261 · Cited by 85
Aldosterone and the Cardiovascular System: Genomic and Nongenomic Effects
Funder, J. W. (2006) · Endocrinology · doi:10.1210/en.2006-0826 · Cited by 82
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Ortiz-Pérez, J. T., Riera, M., Bosch, X., de Caralt, T. M., Perea, R. J., Pascual, J., & Soler, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061695 · Cited by 82
Myofibroblasts in the Infarct Area: Concepts and Challenges
Daskalopoulos, E. P., Janssen, B. J., & Blankesteijn, W. M. (2012) · Microscopy and Microanalysis · doi:10.1017/s143192761101227x · Cited by 90
Treatment for chronic heart failure in the elderly: current practice and problems
Abete, P., Testa, G., Della‐Morte, D., Gargiulo, G., Galizia, G., de Santis, D., Magliocca, A., Basile, C., & Cacciatore, F. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9363-6 · Cited by 93
Großmann, C., Krug, A. W., Freudinger, R., Mildenberger, S., Voelker, K., & Gekle, M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00708.2006 · Cited by 82
Yatabe, J., Yoneda, M., Yatabe, M., Watanabe, T., Felder, R. A., José, P. A., & Sanada, H. (2011) · Endocrinology · doi:10.1210/en.2010-1070 · Cited by 82
Voets, M., Antes, I., Scherer, C., Müller‐Vieira, U., Biemel, K. M., Barassin, C., Marchais‐Oberwinkler, S., & Hartmann, R. W. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503704 · Cited by 85
Selective Aldosterone Blockade Suppresses Atrial Tachyarrhythmias in Heart Failure
Shroff, S. C., Ryu, K., MARTOVITZ, N. L., Hoit, B. D., & Stambler, B. S. (2006) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2006.00372.x · Cited by 84
Blangy, H., Sadoul, N., Dousset, B., Radauceanu, A., Fay, R., Aliot, E., & Zannad, F. (2007) · Europace · doi:10.1093/europace/eum102 · Cited by 81
Self-citationMedical therapy for chronic heart failure
Krum, H., & Teerlink, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61038-6 · Cited by 86
Maron, M. S., Chan, R. H., Kapur, N. K., Jaffe, I. Z., McGraw, A. P., Kerur, R., Maron, B. J., & Udelson, J. E. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.02.025 · Cited by 79
Nishiyama, A. (2018) · Hypertension Research · doi:10.1038/s41440-018-0158-6 · Cited by 89
Towards precision medicine in heart failure
Weldy, C. S., & Ashley, E. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00566-9 · Cited by 89
Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics
Epstein, M., & Calhoun, D. A. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00511.x · Cited by 87
Fujimura, N., Noma, K., Hata, T., Soga, J., Hidaka, T., Idei, N., Fujii, Y., Mikami, S., Maruhashi, T., Iwamoto, Y., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.227 · Cited by 83
Sánchez, M. A. (2004) · Revista Española de Cardiología · doi:10.1016/s0300-8932(04)77258-9 · Cited by 81
Preston, R. A., White, W. B., Pitt, B., Bakris, G. L., NORRIS, P., & Hanes, V. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.12.003 · Cited by 81
Self-citationNakano, S., Kobayashi, N., Yoshida, K., Tomoyuki, O. H. N. O., & Matsuoka, H. (2005) · Hypertension Research · doi:10.1291/hypres.28.925 · Cited by 81
Faris, R. F., Flather, M. D., Purcell, H., Poole-Wilson, P. A., & Coats, A. J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003838.pub2 · Cited by 108
RetractedCurrent treatment options in (peri)myocarditis and inflammatory cardiomyopathy
Maisch, B., & Pankuweit, S. (2012) · Herz · doi:10.1007/s00059-012-3679-9 · Cited by 86
Ulmschneider, S., Müller‐Vieira, U., Klein, C. D. P., Antes, I., Lengauer, T., & Hartmann, R. W. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492397 · Cited by 80
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?
Gekle, M., & Großmann, C. (2008) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-008-0616-0 · Cited by 89
Treatment of hypertension in patients with coronary artery disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.03.002 · Cited by 89
Joffe, H. V., Kwong, R. Y. K., Gerhard‐Herman, M. D., Rice, C., Feldman, K., & Adler, G. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0393 · Cited by 82
Athyros, V. G., Mikhailidis, D. P., Kakafika, A. I., Τζιόμαλος, Κ., & Karagiannis, A. I. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.529 · Cited by 80
Fracture Risk in Men With Congestive Heart Failure
Carbone, L. D., Cross, J. D., Raza, S. H., Bush, A. J., Sepanski, R. J., Dhawan, S., Khan, B. Q., Gupta, M., Ahmad, K., Khouzam, R. N., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.039 · Cited by 79
Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells
Rautureau, Y., Paradis, P., & Schiffrin, E. L. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.015 · Cited by 84
Non–ST-Segment Acute Coronary Syndromes
Hedayati, T., Yadav, N., & Khanagavi, J. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2017.08.003 · Cited by 86
Updates in heart failure 30-day readmission prevention
Goldgrab, D., Balakumaran, K., Kim, M. J., & Tabtabai, S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9754-4 · Cited by 82
Queisser, N., & Schupp, N. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.011 · Cited by 89
TAKEDA, Y., ZHU, A., YONEDA, T., Usukura, M., TAKATA, H., & YAMAGISHI, M. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.05.008 · Cited by 79
Nicolai, M. P. J., Liem, S., Both, S., Pelger, R. C. M., Putter, H., Schalij, M. J., & Elzevier, H. W. (2013) · Netherlands Heart Journal · doi:10.1007/s12471-013-0482-z · Cited by 81
Aldosterone and glomerular podocyte injury
Nagase, M., & Fujita, T. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0034-9 · Cited by 81
Bostick, B., Habibi, J., DeMarco, V. G., Jia, G., Domeier, T. L., Lambert, M. D., Aroor, A. R., Nistala, R., Bender, S. B., Garro, M., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00898.2014 · Cited by 80
The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis
van der Heijden, C. D. C. C., Deinum, J., Joosten, L. A. B., Netea, M. G., & Riksen, N. P. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy092 · Cited by 80
Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
Cannavò, A., Bencivenga, L., Liccardo, D., Elia, A., Marzano, F., Gambino, G., D’Amico, M. L., Perna, C., Ferrara, N., Rengo, G., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1204598 · Cited by 90
Sam, F. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.10.007 · Cited by 79
Kotlyar, E., Vita, J. A., Winter, M. R., Awtry, E. H., Siwik, D. A., Keaney, J. F., Sawyer, D. B., Cupples, L. A., Colucci, W. S., & Sam, F. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.08.005 · Cited by 79
Gheorghiade, M., Albaghdadi, M., Zannad, F., Fonarow, G. C., Böhm, M., Gimpelewicz, C., Botha, J., Moores, S., Lewis, E. F., Rattunde, H., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq209 · Cited by 78
Self-citationSwaminathan, K., Davies, J. I., Casella, G., Rajendra, N. S., Morris, A. D., & Struthers, A. D. (2008) · Diabetologia · doi:10.1007/s00125-008-0972-5 · Cited by 85
Heart of the matter: Coronary dysfunction in metabolic syndrome
Berwick, Z. C., Dick, G. M., & Tune, J. D. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.06.025 · Cited by 81
Lucas, S., Heim, R., Ries, C., Schewe, K. E., Birk, B., & Hartmann, R. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800888q · Cited by 81
Mayyas, F., Alzoubi, K. H., & Wagoner, D. R. V. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.022 · Cited by 82
Spironolactone improves lung diffusion in chronic heart failure
Agostoni, P., Magini, A., Andreini, D., Contini, M., Apostolo, A., Bussotti, M., Cattadori, G., & Palermo, P. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi023 · Cited by 80
Sato, N., Ajioka, M., Yamada, T., Kato, M., Myoishi, M., Yamada, T., Kim, S.-Y., Nowack, C., Kolkhof, P., Shiga, T., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0122 · Cited by 77
Ong, G. S. Y., & Young, M. J. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0318 · Cited by 81
Mazurek, J. A., & Jessup, M. L. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.08.001 · Cited by 81
Cardiovascular Effects of Aldosterone and Post–Acute Myocardial Infarction Pathophysiology
Cohn, J. N., & Colucci, W. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.004 · Cited by 78
An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction
Sun, J.-Y., Du, L.-J., Shi, X.-R., Zhang, Y.-Y., Liu, Y., Wang, Y.-L., Chen, B.-Y., Liu, T., Zhu, H., Liu, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4110 · Cited by 73
Solomon, S. D., Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., Jhund, P. S., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3266 · Cited by 78
Self-citationMcCullough, P. A., Beaver, T. M., Bennett‐Guerrero, E., Emmett, M., Fonarow, G. C., Goyal, A., Herzog, C. A., Kosiborod, M., & Palmer, B. F. (2014) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0727 · Cited by 82
The meaning of hypokalemia in heart failure
Bielecka-Dabrowa, A. M., Mikhailidis, D. P., Jones, L. G., Rysz, J., Aronow, W. S., & Banach, M. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.06.121 · Cited by 77
Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload–Induced Cardiac Injury
Ayuzawa, N., Nagase, M., Ueda, K., Nishimoto, M., Kawarazaki, W., Marumo, T., Aiba, A., Sakurai, T., Shindo, T., & Fujita, T. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06054 · Cited by 81
Cardiovascular Disease in the Elderly
Schwartz, J. B., & Zipes, D. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00080-9 · Cited by 79
Weintraub, W. S., Zhang, Z., Mahoney, E. M., Kolm, P., Spertus, J. A., Caro, J., Ishak, J., Goldberg, R., Tooley, J., Willke, R., et al. (2005) · Circulation · doi:10.1161/01.cir.0000157146.86758.bc · Cited by 77
Self-citationBatenburg, W. W., Jansen, P. M., van den Bogaerdt, A. J., & J. Danser, A. H. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs016 · Cited by 74
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 80
Malgie, J., Clephas, P. R. D., Rocca, H. B., de Boer, R. A., & Brugts, J. J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10325-2 · Cited by 86
Mechanism of heart failure after myocardial infarction
Jiang, H., Fang, T., & Cheng, Z. (2023) · Journal of International Medical Research · doi:10.1177/03000605231202573 · Cited by 90
Vizzardi, E., D’Aloia, A., Giubbini, R., Bordonali, T., Bugatti, S., Pezzali, N., Romeo, A. M., Dei, A., Metra, M., & Cas, L. D. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.052 · Cited by 76
The causes, consequences, and treatment of left or right heart failure
Peteiro, J., Peteiro-Vázquez, J., Gacía-Campos, A., García‐Bueno, L., Abugattás-de-Torres, J. P., & Castro‐Beiras, A. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10669 · Cited by 95
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.